SCHEMBL17942437

SCHEMBL17942437

Cn1cc(S(=O)(=O)C(C)(C)C2CCN(C(=O)O)CC2)c(C(F)(F)F)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.39
CACNA1B Q00975 2/20 0.39
NR1I2 O75469 1/20 0.39
GRIA2 P42262 1/20 0.36
PIK3C3 Q8NEB9 2/20 0.36
KMT2A Q03164 1/20 0.35
RORC P51449 1/20 0.35
GAA P10253 1/20 0.33
HTR7 P34969 1/20 0.33
RBP4 P02753 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
IRAK4 Q9NWZ3 2/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
THRA P10827 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17942454 0.91 KMT2A (0.35) CYP3A4CACNA1BNR1I2GRIA2PIK3C3
SCHEMBL17948989 0.90 CYP3A4 (0.39) CYP3A4CACNA1BNR1I2GRIA2PIK3C3
SCHEMBL17948997 0.87 STS (0.44) KMT2ATHRB
SCHEMBL17942363 0.83 RORC (0.38) CACNA1BGRIA2PIK3C3KMT2ARORC
SCHEMBL17942401 0.82 GRIA2 (0.37) GRIA2PIK3C3RORCIRAK4
SCHEMBL17948958 0.81 RBP4 (0.35) CYP3A4CACNA1BNR1I2GRIA2PIK3C3
SCHEMBL17942510 0.80 KMT2A (0.36) GRIA2PIK3C3KMT2ARORCGAA
SCHEMBL17942530 0.80 PIK3C3 (0.39) CYP3A4CACNA1BNR1I2GRIA2PIK3C3
SCHEMBL17949449 0.80 PIK3C3 (0.39) CYP3A4CACNA1BNR1I2PIK3C3RORC
SCHEMBL29529658 0.80 PIK3C3 (0.39) CYP3A4CACNA1BNR1I2PIK3C3RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4234017-A2 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) MyoKardia, Inc. (US) 2023-08-30 EP disclosed
EP-3247707-B1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) MYOKARDIA INC (US) 2023-05-31 EP disclosed
US-20220117955-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS MyoKardia, Inc. 2022-04-21 US disclosed
US-11123337-B2 4-methylsulfonyl-substituted piperidine urea compounds MyoKardia, Inc. (US) 2021-09-21 US disclosed
US-20200345716-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds MyoKardia, Inc. 2020-11-05 US disclosed
US-10758525-B2 4-methylsulfonyl-substituted piperidine urea compounds MyoKardia, Inc. (US) 2020-09-01 US disclosed
US-20200113887-A9 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS MyoKardia, Inc. 2020-04-16 US disclosed
US-20190269669-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS MYOKARDIA INC (US) 2019-09-05 US disclosed
US-9925177-B2 4-methylsulfonyl-substituted piperidine urea compounds MyoKardia, Inc. (US) 2018-03-27 US disclosed
EP-3247707-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) Myokardia, Inc. (US) 2017-11-29 EP disclosed
US-20160243100-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds MyoKardia, Inc. 2016-08-25 US disclosed
WO-2016118774-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) MyoKardia, Inc. (US) 2016-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200113887-A9 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS TNNI3, UMPS, TNNT2 CYP3A4 4065/4885CACNA1B 1143/4885NR1I2 1440/4885
US-20220117955-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS TNNI3, UMPS, TNNT2 CYP3A4 4065/4885CACNA1B 1143/4885NR1I2 1440/4885
US-10758525-B2 4-methylsulfonyl-substituted piperidine urea compounds TNNI3, UMPS, TNNT2 CYP3A4 4065/4885CACNA1B 1143/4885NR1I2 1440/4885
US-20190269669-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS TNNI3, UMPS, TNNT2 CYP3A4 4065/4885CACNA1B 1143/4885NR1I2 1440/4885
US-20200345716-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds TNNI3, UMPS, TNNT2 CYP3A4 4065/4885CACNA1B 1143/4885NR1I2 1440/4885
US-20160243100-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds TNNI3, UMPS, TNNT2 CYP3A4 4065/4885CACNA1B 1143/4885NR1I2 1440/4885
US-11123337-B2 4-methylsulfonyl-substituted piperidine urea compounds TNNI3, UMPS, TNNT2 CYP3A4 4065/4885CACNA1B 1143/4885NR1I2 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.